Definitive Contract 75F40118C10212

This is a sole source 8(a) contract awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Caitta Inc., an SBA certified economically disadvantaged woman-owned small business (EDWOSB). The contract is for expert witness services in support of the FDA's proposal to withdraw approval of abbreviated new drug applications (ANDAs) for extended-release methylphenidate tablets. The potential contract value is $137,100.00 with a completion date of September 29, 2020. Caitta has a history of providing scientific, technical, and administrative services to federal agencies like the FDA, National Institutes of Health (NIH), and National Institute of Standards and Technology (NIST), through both competitive and set-aside contracts. This contract appears to be part of a larger FDA indefinite delivery vehicle that allows Caitta to provide ongoing benefit, risk, and quality assessment services.